Erratum to: Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8, (780-788), 10.1002/ajh.24770)

Najibah A. Galadanci; Shehu Umar Abdullahi; Leah D. Vance; Abdulkadir Musa Tabari; Shehi Ali; Raymond Belonwu; Auwal Salihu; Aisha Amal Galadanci; Binta Wudil Jibir; Halima Bello-Manga; Kathleen Neville; Fenella J. Kirkham; Yu Shyr; Sharon Phillips; Brittany V. Covert; Adetola A. Kassim; Lori C. Jordan; Muktar H. Aliyu; Michael R. DeBaun

doi:10.1002/ajh.25012

Erratum to: Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8, (780-788), 10.1002/ajh.24770)

Najibah A. Galadanci, Shehu Umar Abdullahi, Leah D. Vance, Abdulkadir Musa Tabari, Shehi Ali, Raymond Belonwu, Auwal Salihu, Aisha Amal Galadanci, Binta Wudil Jibir, Halima Bello-Manga, Kathleen Neville, Fenella J. Kirkham, Yu Shyr, Sharon Phillips, Brittany V. Covert, Adetola A. Kassim, Lori C. Jordan, Muktar H. Aliyu, Michael R. DeBaun

Department of Statistics

Research output: Contribution to journal › Comment/debate › peer-review

6 Citations (Scopus)

Abstract

We wish to formally correct the above-referenced article and omit mention utilization of the Morisky medication adherence scale. The Morisky medication adherence scale was used to access study participants adherence on a monthly basis by parental recall.We did not realize that the questions were protected by copyright and required permission for utilization. For the duration of the study, the adherence tool is used as a secondary measurement of adherence, while the primary indicator included change in mean cell volume. The removal of the Morisky scale adherence data does not affect the primary outcomes of the study and does not alter the evidence of adherence, because increase in MCV was the primary measure of adherence. All the authors of the manuscript have been informed of the changes and have agreed to the publication of an erratum. We apologize for any inconvenience that this error might have caused.

Original language	English
Pages (from-to)	E83
Journal	American Journal of Hematology
Volume	93
Issue number	3
DOIs	https://doi.org/10.1002/ajh.25012
Publication status	Published - 2018 Mar

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1002/ajh.25012

Cite this

Galadanci, N. A., Umar Abdullahi, S., Vance, L. D., Musa Tabari, A., Ali, S., Belonwu, R., Salihu, A., Amal Galadanci, A., Wudil Jibir, B., Bello-Manga, H., Neville, K., Kirkham, F. J., Shyr, Y., Phillips, S., Covert, B. V., Kassim, A. A., Jordan, L. C., Aliyu, M. H., & DeBaun, M. R. (2018). Erratum to: Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8, (780-788), 10.1002/ajh.24770). American Journal of Hematology, 93(3), E83. https://doi.org/10.1002/ajh.25012

@article{312a06817080482d8bea55d199ba9523,

title = "Erratum to: Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8, (780-788), 10.1002/ajh.24770)",

abstract = "We wish to formally correct the above-referenced article and omit mention utilization of the Morisky medication adherence scale. The Morisky medication adherence scale was used to access study participants adherence on a monthly basis by parental recall.We did not realize that the questions were protected by copyright and required permission for utilization. For the duration of the study, the adherence tool is used as a secondary measurement of adherence, while the primary indicator included change in mean cell volume. The removal of the Morisky scale adherence data does not affect the primary outcomes of the study and does not alter the evidence of adherence, because increase in MCV was the primary measure of adherence. All the authors of the manuscript have been informed of the changes and have agreed to the publication of an erratum. We apologize for any inconvenience that this error might have caused.",

author = "Galadanci, {Najibah A.} and {Umar Abdullahi}, Shehu and Vance, {Leah D.} and {Musa Tabari}, Abdulkadir and Shehi Ali and Raymond Belonwu and Auwal Salihu and {Amal Galadanci}, Aisha and {Wudil Jibir}, Binta and Halima Bello-Manga and Kathleen Neville and Kirkham, {Fenella J.} and Yu Shyr and Sharon Phillips and Covert, {Brittany V.} and Kassim, {Adetola A.} and Jordan, {Lori C.} and Aliyu, {Muktar H.} and DeBaun, {Michael R.}",

note = "Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2018",

month = mar,

doi = "10.1002/ajh.25012",

language = "English",

volume = "93",

pages = "E83",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "3",

}

Galadanci, NA, Umar Abdullahi, S, Vance, LD, Musa Tabari, A, Ali, S, Belonwu, R, Salihu, A, Amal Galadanci, A, Wudil Jibir, B, Bello-Manga, H, Neville, K, Kirkham, FJ, Shyr, Y, Phillips, S, Covert, BV, Kassim, AA, Jordan, LC, Aliyu, MH & DeBaun, MR 2018, 'Erratum to: Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8, (780-788), 10.1002/ajh.24770)', American Journal of Hematology, vol. 93, no. 3, pp. E83. https://doi.org/10.1002/ajh.25012

Erratum to: Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8, (780-788), 10.1002/ajh.24770). / Galadanci, Najibah A.; Umar Abdullahi, Shehu; Vance, Leah D. et al.
In: American Journal of Hematology, Vol. 93, No. 3, 03.2018, p. E83.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Erratum to

T2 - Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8, (780-788), 10.1002/ajh.24770)

AU - Galadanci, Najibah A.

AU - Umar Abdullahi, Shehu

AU - Vance, Leah D.

AU - Musa Tabari, Abdulkadir

AU - Ali, Shehi

AU - Belonwu, Raymond

AU - Salihu, Auwal

AU - Amal Galadanci, Aisha

AU - Wudil Jibir, Binta

AU - Bello-Manga, Halima

AU - Neville, Kathleen

AU - Kirkham, Fenella J.

AU - Shyr, Yu

AU - Phillips, Sharon

AU - Covert, Brittany V.

AU - Kassim, Adetola A.

AU - Jordan, Lori C.

AU - Aliyu, Muktar H.

AU - DeBaun, Michael R.

PY - 2018/3

Y1 - 2018/3

N2 - We wish to formally correct the above-referenced article and omit mention utilization of the Morisky medication adherence scale. The Morisky medication adherence scale was used to access study participants adherence on a monthly basis by parental recall.We did not realize that the questions were protected by copyright and required permission for utilization. For the duration of the study, the adherence tool is used as a secondary measurement of adherence, while the primary indicator included change in mean cell volume. The removal of the Morisky scale adherence data does not affect the primary outcomes of the study and does not alter the evidence of adherence, because increase in MCV was the primary measure of adherence. All the authors of the manuscript have been informed of the changes and have agreed to the publication of an erratum. We apologize for any inconvenience that this error might have caused.

AB - We wish to formally correct the above-referenced article and omit mention utilization of the Morisky medication adherence scale. The Morisky medication adherence scale was used to access study participants adherence on a monthly basis by parental recall.We did not realize that the questions were protected by copyright and required permission for utilization. For the duration of the study, the adherence tool is used as a secondary measurement of adherence, while the primary indicator included change in mean cell volume. The removal of the Morisky scale adherence data does not affect the primary outcomes of the study and does not alter the evidence of adherence, because increase in MCV was the primary measure of adherence. All the authors of the manuscript have been informed of the changes and have agreed to the publication of an erratum. We apologize for any inconvenience that this error might have caused.

UR - http://www.scopus.com/inward/record.url?scp=85041283687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041283687&partnerID=8YFLogxK

U2 - 10.1002/ajh.25012

DO - 10.1002/ajh.25012

M3 - Comment/debate

C2 - 29411418

AN - SCOPUS:85041283687

SN - 0361-8609

VL - 93

SP - E83

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 3

ER -

Erratum to: Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) (American Journal of Hematology, (2017), 92, 8, (780-788), 10.1002/ajh.24770)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this